首页> 外文期刊>Analytical methods >Development of a novel parallel determination platform: a feasibility study tested on a chemiluminescence device
【24h】

Development of a novel parallel determination platform: a feasibility study tested on a chemiluminescence device

机译:新型平行测定平台的开发:在化学发光装置上测试的可行性研究

获取原文
           

摘要

The potential of obtaining incremental diagnostic information using a parallel assay is attractive. Herein, a novel parallel determination platform was developed for the simultaneous determination of hormones, including human growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Polystyrene was used as a support material and the device comprised an antibody capture area, a connecting channel, and an isolating bar. After immobilizing antibodies in the antibody capture area, 50 μL antigens and 1.5 mL of HRP-labelled antibodies were mixed and bound to the capture antibodies by flowing in the connecting channel continually. After adding chemiluminescence substrates, the isolating bar enabled the connecting channel to enter into the detection site in a 1?:?1 ratio. Fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) was used as an internal standard. The developed method was validated in terms of limits of detection (LOD), linearity, recovery and precision. The LOD were 0.01 mIU L?1, 0.01 IU L?1, 0.03 mIU L?1, 0.05 mIU L?1, and 0.01 IU L?1 for GH, FSH, TSH, PRL, and LH, respectively. The assay was linear up to 230 mIU L?1 for GH (r2 = 0.995), 300 IU L?1 for FSH (r2 = 0.991), 100 mIU L?1 for TSH (r2 = 0.997), 8000 mIU L?1 for PRL (r2 = 0.994), and 260 IU L?1 for LH (r2 = 0.992). The mean recoveries were calculated at two concentration levels and the values were found to be between 90.5% and 108.3%. The intra- and inter-assay coefficients of variation were 10% and 11%, respectively. The method was successfully applied to determine serum sample (n = 120) and the results were strongly correlated with the Siemens and Abbott immunoassay, showing a bias offset of 1.7 mIU L?1, 2.4 IU L?1, 0.1 mIU L?1, 7.6 mIU L?1 and 1.5 IU L?1 for GH, FSH, TSH, PRL, and LH. This sensitive and cost-efficient platform is expected to be a powerful tool to measure combinations of various biomarkers.
机译:使用平行测定获得增量诊断信息的潜力具有吸引力。在此,开发了一种新型的平行测定平台,用于同时测定激素,包括人体生长激素(GH),催乳激素(PRL),促甲状腺激素(TSH),促卵泡激素(FSH)和促黄体生成激素(LH) 。聚苯乙烯用作支撑材料,该设备包含抗体捕获区域,连接通道和隔离条。将抗体固定在抗体捕获区域后,将50μL抗原和1.5 mL HRP标记的抗体混合并通过持续在连接通道中流动而与捕获抗体结合。添加化学发光底物后,隔离条使连接通道以1?:?1的比例进入检测部位。异硫氰酸荧光素标记的牛血清白蛋白(FITC-BSA)用作内标。所开发的方法在检测限(LOD),线性,回收率和精密度方面得到了验证。 GH,FSH,TSH,PRL和LH的LOD分别为0.01 mIU L?1、0.01 IU L?1、0.03 mIU L?1、0.05 mIU L?1和0.01 IU L?1。对于GH(r2 = 0.995),测定高达300 mIU L?1;对于FSH(r2 = 0.991),测定为300 IU L?1;对于TSH(r2 = 0.997),100 mIU L?1; 8000 mIU L?1 PRL(r2 = 0.994),LH为260 IU L?1(r2 = 0.992)。计算了两个浓度水平的平均回收率,发现回收率在90.5%和108.3%之间。批内和批间变异系数分别<10%和<11%。该方法已成功应用于血清样品的检测(n = 120),其结果与西门子和雅培免疫分析法密切相关,显示偏差分别为1.7 mIU L?1、2.4 IU L?1、0.1 mIU L?1, GH,FSH,TSH,PRL和LH分别为7.6 mIU L?1和1.5 IU L?1。这个灵敏且具有成本效益的平台有望成为衡量各种生物标记物组合的有力工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号